Business Context and Reporting Period
OrthoPediatrics Corp. (KIDS) filed this Form 8-K on June 4, 2019, reporting the completion of a material acquisition and related financing activities. The Company, an emerging growth company incorporated in Delaware, operates in the medical device sector focusing on pediatric orthopedics.
Key Financial Metrics and Transaction Details
Acquisition Consideration
- Total Consideration: Approximately $60 million in cash and stock.
- Cash Component: $50 million (subject to working capital adjustments), with $3 million held in escrow for 20 months.
- Stock Component: 245,352 shares of Common Stock valued at $40.76 per share (based on 30-day VWAP ending May 30, 2019).
Debt Financing
- New Facility: $30 million Term Loan B added to existing facilities.
- Existing Facilities: $20 million Term Loan A and $15 million revolving credit facility.
- Interest Rate: Greater of (3-month LIBOR + 8.61%) or 10.00%.
- Maturity: Term Loan B matures on May 31, 2020, or earlier upon a change of control or sale of Vilex assets. Term Loan A and revolver mature January 31, 2023.
- Covenants: No borrowings permitted under the revolving facility until Term Loan B and accrued interest are paid in full.
Note: This filing does not provide specific revenue, profit, cash flow, or margin figures for the reporting period.
Material Changes and Strategic Actions
Acquisition of Vilex Companies
The Company acquired 100% of Vilex in Tennessee, Inc. and Orthex, LLC (collectively "Vilex Companies"). These entities manufacture foot and ankle surgical implants and Orthex Hexapod technology for pediatric congenital deformities.
Planned Divestiture
Management has been authorized to divest non-core adult product lines from the Vilex Companies. The Company intends to identify assets, pricing, and buyers over the coming weeks.
Collateral and Guarantees
Borrowings are secured by substantially all Company assets. Orthex and Vilex stock/membership interests were granted as collateral. Borrowings are unconditionally guaranteed by subsidiaries, excluding Vilex.
Guidance, Risks, and Unusual Items
- Forward-Looking Statements: The Company cautions that statements regarding the divestiture of non-core assets and the timing of such transactions involve risks and uncertainties.
- Financial Reporting: Pro forma financial information and financial statements of the acquired businesses are not included in this filing but will be submitted in an amendment within 71 days.
- Risk Factors: Risks include the ability to successfully manage the divestiture process and realize anticipated benefits. General risks are referenced from the 2018 Form 10-K.
Investor Verification Checklist
- Verify the final purchase price adjustments related to working capital and the $3 million escrow release terms.
- Monitor the upcoming 71-day amendment for pro forma financial data to assess the acquisition's impact on earnings and leverage.
- Track the progress of the divestiture of non-core adult product lines to ensure alignment with the pediatric-focused strategy.
- Review the impact of the new $30 million Term Loan B on the Company's liquidity and interest expense, noting the 10% minimum interest rate.
- Confirm the status of the revolving credit facility, which is currently restricted until the Term Loan B is repaid.